What America Needs From a New FDA Commissioner

Article excerpt

The U.S. biotech industry faces an existential crisis, hamstrung by a sluggish FDA and outmaneuvered by China's aggressive industrial policy, according to this analysis. While AI breakthroughs promise faster and cheaper drug development, regulatory bottlenecks are squandering America's technological advantage. The incoming administration, known for prioritizing American interests, must overhaul FDA leadership and reform approval processes to restore competitive edge, or risk watching the biotech sector continue its erosion to foreign competitors.